决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Leukocyte immunoglobulin-like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond.
这些研究强调了进一步研究LILRB4在肿瘤微环境中相互作用的必要性,并突出了其作为肿瘤学治疗靶点及未来临床创新的重要性。
白细胞免疫球蛋白样受体B4(LILRB4)对免疫调节以及多种癌症的发病和进展具有显著影响。本综述讨论了LILRB4的结构特征、在免疫细胞中的表达模式以及在调节免疫应答中的分子机制。我们描述了LILRB4对T细胞、树突状细胞、NK细胞和巨噬细胞的影响,及其在刺激和抑制免疫活动中的双重作用。本综述讨论了目前关于LILRB4参与急性髓系白血病、慢性淋巴细胞白血病以及实体瘤(如结直肠癌、胰腺癌、非小细胞肺癌、肝细胞癌和髓外多发性骨髓瘤)的研究。本综述还描述了LILRB4在自身免疫性疾病、感染性疾病及其他病症中的作用。我们评估了利用单克隆抗体和肽抑制剂靶向LILRB4的最新进展及其在癌症治疗中的治疗潜力。总之,这些研究强调了进一步研究LILRB4在肿瘤微环境中相互作用的必要性,并突出了其作为肿瘤学治疗靶点及未来临床创新的重要性。
Leukocyte immunoglobulin-like receptor B4 (LILRB4) significantly impacts immune regulation and the pathogenesis and progression of various cancers. This review discusses LILRB4's structural attributes, expression patterns in immune cells, and molecular mechanisms in modulating immune responses. We describe the influence of LILRB4 on T cells, dendritic cells, NK cells, and macrophages, and its dual role in stimulating and suppressing immune activities. The review discusses the current research on LILRB4's involvement in acute myeloid leukemia, chronic lymphocytic leukemia, and solid tumors, such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, hepatocellular carcinoma, and extramedullary multiple myeloma. The review also describes LILRB4's role in autoimmune disorders, infectious diseases, and other conditions. We evaluate the recent advancements in targeting LILRB4 using monoclonal antibodies and peptide inhibitors and their therapeutic potential in cancer treatment. Together, these studies underscore the need for further research on LILRB4's interactions in the tumor microenvironment and highlight its importance as a therapeutic target in oncology and for future clinical innovations.
MEMBER ACCOUNT
登录成功会直接打开下一页。